Eagle Pharmaceuticals Announces Positive Type C Meeting with FDA for EA-114, an Estrogen Receptor Antagonist Used in the Treatment of Metastatic Breast Cancer in Post-Menopausal Women
29. August 2023 06:50 ET
|
Eagle Pharmaceuticals, Inc.
Eagle plans to file a new drug application (“NDA”) for EA-114 in 2024 EA-114 is anticipated to meaningfully optimize the dosing regimen for all fulvestrant patients and provide the opportunity for...
Eagle Pharmaceuticals to Present at Two Upcoming Healthcare Conferences
22. August 2023 16:05 ET
|
Eagle Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian...
Eagle Pharmaceuticals Reiterates 2023 Adjusted non-GAAP EBITDA and Adjusted non-GAAP E¹ Guidance
17. August 2023 06:50 ET
|
Eagle Pharmaceuticals, Inc.
-- FY 2023 Adjusted non-GAAP EBITDA expected to be $78.0 - $84.0 million1 ---- FY 2023 Adjusted non-GAAP earnings per share expected to be $4.40 - $4.701 ---- Reflects strength of Eagle’s business and...
Eagle Pharmaceuticals Reports Second Quarter 2023 Results
08. August 2023 06:50 ET
|
Eagle Pharmaceuticals, Inc.
• Total revenue for Q2 2023 was $64.6 million • Q2 2023 net income was $0.39 per basic and diluted share and adjusted non-GAAP net income1 was $1.18 per basic and diluted share • Q2 2023 net income...
Eagle Pharmaceuticals to Host Second Quarter 2023 Financial Results on August 8, 2023
01. August 2023 06:50 ET
|
Eagle Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its second quarter 2023...
Eagle Pharmaceuticals Raises 2023 Adjusted non-GAAP EPS¹ Guidance
31. Juli 2023 06:50 ET
|
Eagle Pharmaceuticals, Inc.
-- FY 2023 Adjusted non-GAAP earnings per share now expected to be $4.40 - $4.701 ---- FY 2023 Adjusted non-GAAP EBITDA expected to be $78.0 - $84.0 million1 ---- FY 2023 Adjusted non-GAAP R&D...
Eagle Pharmaceuticals Announces First Patient Randomized in Phase 2 Study Evaluating CAL02, a Novel First-in-Class Anti-Toxin Drug Candidate, in Severe Community-Acquired Bacterial Pneumonia (SCABP)
24. Juli 2023 06:50 ET
|
Eagle Pharmaceuticals, Inc.
Despite the availability of antibiotics, the death rate from pneumonia in the U.S. has seen little improvement in the past half century1 – CAL02 is a unique therapeutic agent that works differently...
Eagle Pharmaceuticals Provides Business Update and Reiterates 2023 Guidance
15. Juni 2023 06:50 ET
|
Eagle Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided a business update and reiterated its 2023 financial...
Eagle Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) and Fast-Track Designation for CAL02, Providing Five-Year Exclusivity Extension
14. Juni 2023 06:50 ET
|
Eagle Pharmaceuticals, Inc.
– Company believes CAL02 is a new chemical entity (NCE), which would result in five years of marketing exclusivity upon approval or three years without NCE designation; total potential of eight or ten...
Eagle Pharmaceuticals Announces Acceptance of Two Abstracts at the Society for Academic Emergency Medicine (SAEM) Annual Meeting
11. Mai 2023 06:50 ET
|
Eagle Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that two abstracts were accepted for presentation at the...